Dexcom Steven Cohen and Point72 Asset Management bought over 900,000 shares of Dexcom (NASDAQ: DXCM) during the second quarter. Runaway inflation and rising interest rates are making bears out of investors and keeping stock markets under pressure this year. In the U.S., the Food and Drug Administration (FDA) is expected to clear the G7 late this year because some last-minute software changes delayed the application process.